Investigation Overview
October 13, 2014 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Durata Therapeutics Inc (NASDAQ:DRTX), was announced concerning whether the takeover of Durata Therapeutics Inc by Actavis plc for $23 per share is unfair to NASDAQ:DRTX stockholders. The investigation by a law firm concerns whether certain officers and directors of Dur...
You must register (for free) or login to view the entire investigation.